FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 Join the Great American Smokeout for a Healthier Tomorrow November 14, 2023 Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced April 21, 2021 First Global Estimates of Cervical Cancer Attributable to HIV November 30, 2020 Load more HOT NEWS FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations Middle Schooler Starts Business to Help Provide Spa and Salon Services... Receiving a Blood Transfusion During Cancer: What to Know and What...
